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72 Antimicrobial activity of stable allicin against multiresistant cystic
ﬁbrosis pathogens
C. Doherty1, D. Wallock2, L. Doherty1, D. Clarke2, D. Campopiano2, J.R. Govan1.
1University of Edinburgh, Centre for Infectious Diseases, Edinburgh, United
Kingdom; 2University of Edinburgh, Chemistry, Edinburgh, United Kingdom
Background: The antimicrobial activity of garlic and other alliums are primarily
based on allicin, an unstable thiosulphinate present in crushed garlic bulbs but
absent in medicinal formulations.
Objectives: To determine if stabilised allicin exhibits antimicrobial properties
against multiresistant CF pathogens.
Methods: We investigated 81 isolates comprising the Burkholderia cepacia com-
plex, Stenotrophomonas maltophilia and multiresistant strains of Pseudomonas
aeruginosa. Inhibitory activity (MIC and MBC) of stabilised allicin (NAM: New
AllicinMAX TM) was determined using concentrations from 15−90mg/L. Bacteri-
cidal activity was measured by a kill curve in the presence of 3*MBC.
Results: All bacterial isolates were inhibited by NAM with MIC values in the
range 15−60mg/L. A kill curve using P. aeruginosa PAO1 at an initial density
of 106 CFU/ml showed 100% killing within 60 min. To understand the potency
of the chemically complex NAM, mass spectrometry was used to identify the
active component(s) and their impact on bacterial protein targets. The potential
for synergistic activity between NAM and conventional antibiotics has also been
explored.
Conclusion: Unlike other garlic extracts, NAM retains bactericidal properties
against B. cepacia complex, S. maltophilia and multiresistant P. aeruginosa. Present
therapy against these pathogens is difﬁcult and NAM merits further investigation.
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The development and clinical exploitation of antibiotics with new modes of
action are a top priority in ﬁghting untreatable chronic infections in CF patients.
POL7001 is a Protein Epitope Mimetic (PEM) antibiotic with potent activity against
Pseudomonas aeruginosa (PA) (Srinivas et al, Science 2010).
To evaluate CF lung infections as potential clinical application of this new antibiotic,
the activity of POL7001 was tested in vitro against PA isolated from the onset of
infection up to 16 years or until death/lung transplantation in CF patients, and
in murine models of acute and chronic lung infection. Comparison to clinically
approved antibiotics was included.
MICs for POL7001 ranged between 0.015−0.5mg/mL with a median of
0.125mg/mL for all isolates with no difference against mucoid, non-mucoid or
hypermutable isolates. Over time, many of the CF PA isolates became resistant to
antibiotics while remaining sensitive to POL7001. Mice were infected with a multi-
drug resistant PA isolate and treated with POL7001 or ciproﬂoxacin. Subcutaneous
administration showed a comparable efﬁcacy of both antibiotics, with more than
1.5 log10 CFU/mL reduction after 24 hrs, while intratracheal administration showed
faster killing and better efﬁcacy of POL7001 than ciproﬂoxacin, with 3 log10 and
1 log10 CFU/mL reduction after 24 hrs, respectively. In a model of chronic lung
infection daily subcutaneous treatment showed that POL7001 is more efﬁcacious
than ciproﬂoxacin, with 1 log10 CFU/mL reduction in the BAL. These results
represent a step forward in the pre-clinical development of POL7001 to treat CF
lung infections.
Supported by EU (project NABATIVI), Italian CF Research Foundation.
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Lynovex® (cysteamine) has been developed as a unique, dual mucolytic-
antimicrobial agent for the treatment of cystic ﬁbrosis (CF). With a well established
safety proﬁle, Lynovex® has recently been designated as an orphan drug by the
European Medicines Agency.
The antimicrobial activity of Lynovex® was determined using CLSI method M07-
A8 and a microﬂuidic system was applied for determining the ability of Lynovex®
to disrupt and/or prevent CF-relevant bacterial bioﬁlms.
Lynovex® demonstrated broad spectrum antimicrobial activity against P. aeruginosa
and other CF bacterial pathogens including antibiotic-resistant strains with a
MIC100 of 250mg/L, and was not sensitive to the altered ionic conditions that
typify the CF lung. Importantly, Lynovex® demonstrated antimicrobial synergy with
colistin and additivity with ciproﬂoxacin, tobramycin and gentamicin (up to 32-fold
reduction of the antibiotic MIC when combined to Lynovex®). Lynovex® disrupted
established bacterial bioﬁlms at 1000mg/L alone and showed additive activity
with tobramycin at 125/2mg/L (Lynovex®/tobramycin, FIC = 0.63). Lynovex®
outperformed all currently available mucolytic agents in its ability to increase the
viscosity of isolated mucins. In vivo experiments were performed in murine models
of acute P. aeruginosa lung infection in which Lynovex® was administered via
intratracheal delivery or nebulisation. In both systems, Lynovex® was very well
tolerated and reduced lung P. aeruginosa burden.
Lynovex® is a new orphan drug that offers the potential for a step-change in CF
treatment. As a co-therapy alongside existing antibiotic regimens, Lynovex® can
tackle CF respiratory infections directly whilst at the same time disrupting the
mucous and preventing bioﬁlms that facilitate the persistence of these microbes in
the CF lung. Clinical trials of this ﬁrst-in-class drug candidate will commence in
2012.
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Lung infection by Pseudomonas aeruginosa is the key mortality factor for Cystic
Fibrosis patients. The failure of antimicrobials is partly attributed to the increase in
antibiotic tolerance of P. aeruginosa grown in bioﬁlms within the lungs. Therefore,
strategies that improve antibiotic sensitivity of tolerant P. aeruginosa cells may
reduce disease progression. Mannitol has been shown in Escherichia coli to restore
aminoglycoside sensitivity by generating a proton-motive force (Nature, 2011, 473:
216). Here, we show that the commonly used aminoglycoside tobramycin selects for
tolerant cells during bioﬁlm growth by P. aeruginosa and incubation with mannitol
(10−20mM) increased tobramycin sensitivity (up to 1,000-fold). In contrast, NaCl
(up to 30mM) had a lower effect on the sensitivity of tolerant cells suggesting
that the mannitol effect is not related to only an osmotic change but also to its
metabolic properties. At large concentrations (50 and 100mM), NaCl and mannitol
similarly reduced tobramycin tolerance of the bioﬁlm. These results suggest that
in addition to improvements in lung function by facilitating mucus clearance in
CF, mannitol also affects antibiotic sensitivity in bioﬁlms by at least two distinct
and complementary mechanisms. Mannitol alters the tolerance of persister cells
through an osmotic effect at higher concentrations and as a substrate increases
aminoglycoside sensitivity even at low concentrations.
